Your browser version may not work well with NCBI's Web applications. More information here...
1: Cancer Res. 2002 Nov 1;62(21):6035-8.
Related Articles, Links
Click here to read
Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications.

Chang Q, Li Y, White MF, Fletcher JA, Xiao S.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

Insulin receptor substrate 1 (IRS-1) is a major substrate of insulin, insulin-like growth factors, and cytokine signaling and plays an important role in mediating apoptosis, cell differentiation, and cell transformation. We found that IRS-1 is constitutively activated in a variety of solid tumors, including breast cancers, leiomyomas, Wilms' tumors, rhabdomyosarcomas, liposarcomas, leiomyosarcomas, and adrenal cortical carcinomas. Blocking the constitutively activated IRS-1 signaling in breast cancer cells with a dominant-negative IRS-1, an IRS-1 with all 18 potential tyrosine-phosphorylation sites replaced by phenylalanines (F18), dramatically reduced cancer cell growth. Breast cancer cells that expressed F18 also formed smaller and far fewer colonies in soft agar culture than did the cells that did not express F18. These studies suggest that constitutive IRS-1 activation is a common phenomenon in tumors and that activated IRS-1 may present an attractive therapeutic target.

Publication Types:
PMID: 12414625 [PubMed - indexed for MEDLINE]